HELSINKI: A Finnish biopharmaceutical company is selected for the first time to present at the Cavendish Global Health Impact Forum scheduled for May 10 to 14 in the USA.The Oulu-based Paras Biopharmaceuticals Finland Oy, an upcoming manufacturer of biosimilars and therapeutic peptides, will take part in the forum at La Jolla, California, the company said in a press release on Tuesday.
The purpose of the forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programmes within health and the life sciences, the release said.
Cavendish impact forums are hosted by leading institutions across the globe including the University of California, San Diego, the J. Craig Venter Institute, the Scripps Research Institute, the Sanford-Burnham Medical Research Institute, the Sanford Consortium for Regenerative Medicine, and the Institute of the Americas.
